Phase II
KOL event to be held ahead of expected data release with elafibranor in PBC by end of 2018 (Phase 2) and in NASH end of 2019 (Phase 3)
PTC Therapeutics announced interim data from Part 1 of its open-label clinical trials, FIREFISH and SUNFISH, of risdiplam for Type 1, 2 and 3 spinal muscular atrophy in collaboration with Genentech.
Yesterday, top-line data from Bionomics Limited revealed details of the biopharmaceutical company’s Phase II clinical trial of BNC210 in regards to patients with post traumatic stress disorder.
Trial did not meet primary endpoint of decrease in PTSD symptoms as measured by CAPS-5 at 12 weeks
Data Supports Akari’s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous C5 and Leukotriene B4 (LTB4) Activity
Shares of Cambridge, Mass.-based Avrobio plunged more than 50 percent on Monday after the company provided an updated look at its gene therapy for Fabry disease that showed promise for the treatment, but also raised some concern for investors.
Linzagolix overall efficacy and safety maintained or improved at week 24
Updated data show continued reductions in body weight and decreased appetite in patients with rare genetic disorders of obesity
Allergy Therapeutics plc today announces preliminary results for the year ended 30 June 2018.
Geron Corporation, located in Menlo Park, Calif., announced that Janssen Biotech, a Johnson & Johnson company, had terminated their 2014 Collaboration and License Agreement.
PRESS RELEASES